- Home
- GAME vs NSRX Comparison
GAME vs NSRX Comparison
Compare GAME & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | NSRX |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.8M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAME | NSRX |
|---|---|---|
| Price | $0.42 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 8.6M | 46.1K |
| Earning Date | 04-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $1.98 |
| 52 Week High | $2.87 | $9.99 |
Technical Indicators
Market Signals| Indicator | GAME | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.16 | 36.77 |
| Support Level | $0.40 | $1.98 |
| Resistance Level | $0.48 | $5.20 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 78.45 | 46.88 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.